Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 2,080,000 shares, a decrease of 16.8% from the February 13th total of 2,500,000 shares. Based on an average trading volume of 522,500 shares, the days-to-cover ratio is presently 4.0 days. Approximately 17.5% of the company's stock are sold short.

Analyst Upgrades and Downgrades

Several research firms have recently commented on JSPR. JMP Securities restated a "market outperform" rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada dropped their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a research report on Thursday, January 9th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target for the company. UBS Group assumed coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $62.50.

Remove Ads

Institutional Trading of Jasper Therapeutics

Several large investors have recently made changes to their positions in the business. FMR LLC acquired a new position in Jasper Therapeutics during the third quarter valued at $722,000. BNP Paribas Financial Markets lifted its holdings in shares of Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after buying an additional 1,698 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock worth $129,000 after buying an additional 3,873 shares during the last quarter. Ally Bridge Group NY LLC grew its holdings in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock worth $7,514,000 after acquiring an additional 180,852 shares during the period. Finally, Verition Fund Management LLC purchased a new position in Jasper Therapeutics during the third quarter valued at approximately $477,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Trading Down 1.9 %

Shares of NASDAQ:JSPR traded down $0.10 on Friday, hitting $5.21. 176,145 shares of the company were exchanged, compared to its average volume of 268,678. The stock's 50 day moving average price is $5.79 and its 200 day moving average price is $15.30. Jasper Therapeutics has a 1-year low of $4.55 and a 1-year high of $31.01. The firm has a market capitalization of $78.26 million, a P/E ratio of -1.10 and a beta of 2.23.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). On average, equities analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.